Grace Therapeutics (GRCE) Operating Expenses (2019 - 2026)
Grace Therapeutics (GRCE) posted Operating Expenses of $3.0 million for Q1 2026, up 22.91% sequentially from $2.4 million in Q4 2025, and down 5.44% YoY from $3.2 million in Q1 2025.
Grace Therapeutics (GRCE) Operating Expenses (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $3.0 million in Q1 2026.
- Quarterly Operating Expenses fell 5.44% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 33.59% YoY) and the FY2026 annual result came in at $11.1 million, down 33.59% from the prior year.
- Operating Expenses grew to $3.0 million in Q1 2026 per GRCE's latest filing, from $2.4 million in the prior quarter.
- Over five years, Operating Expenses peaked at $5.0 million in Q2 2024 and troughed at $1.8 million in Q3 2022.
- A 5-year average of $3.5 million and a median of $3.3 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses plunged 48.73% in 2022, then jumped 130.93% in 2024.
- Over 5 years, Operating Expenses stood at $4.0 million in 2022, then decreased by 24.66% to $3.0 million in 2023, then grew by 21.72% to $3.7 million in 2024, then sank by 33.88% to $2.4 million in 2025, then grew by 22.91% to $3.0 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $3.0 million, $2.4 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | 2.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.38 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 3.09 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Dec 31, 2024 | 3.70 Mn |
| Sep 30, 2024 | 4.83 Mn |
| Jun 30, 2024 | 4.96 Mn |
| Mar 31, 2024 | 3.26 Mn |
| Dec 31, 2023 | 3.04 Mn |
| Sep 30, 2023 | 2.09 Mn |
| Jun 30, 2023 | 4.45 Mn |
| Mar 31, 2023 | 4.07 Mn |
| Dec 31, 2022 | 4.04 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 4.51 Mn |
| Mar 31, 2022 | 4.15 Mn |
| Dec 31, 2021 | 3.99 Mn |
| Sep 30, 2021 | 3.54 Mn |